(SeaPRwire) –   HERZLIYA, Israel and CALGARY, AB, April 6, 2026 — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF), referred to as the “Company” or “Innocan,” has finalized its previously disclosed offering of an additional debenture (the “Debenture”) to its primary shareholder, Tamar Innovest Ltd. (“Tamar Innovest”). This transaction, termed the “Offering,” generated gross proceeds of US $200,000. This latest offering comes after Tamar Innovest previously acquired a debenture with a principal amount of $450,000 on March 11, 2026.

The Debenture carries an annual interest rate of 10% and will mature at the earlier of two events: (i) 12 months from its issuance date, or (ii) the successful conclusion of the Company’s previously announced proposed public offering in the United States, as outlined in its amended F-1 registration statement filed with the U.S. Securities and Exchange Commission. This Debenture is secured by the general security agreement that the parties established on March 7, 2025, along with the associated security interest registered under Alberta provincial law.

Related Party Transaction Disclosure

Tamar Innovest presently holds beneficial ownership and control over 765,020 Common Shares, which constitutes 17.00% of the Company’s currently issued and outstanding Common Shares, making it an insider of the Company. Ralph Bossino, who is a director of the Company, manages Tamar Innovest. Consequently, Tamar Innovest’s involvement in the Offering is classified as a “related party transaction” under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). The Company plans to utilize the exemptions from the valuation and minority approval stipulations of MI 61-101, as outlined in subsections 5.5(a) and 5.7(a) of MI 61-101, respectively. This is because the fair market value of the Offering will not exceed 25% of the Company’s market capitalization, calculated according to MI 61-101. The Offering received approval from the Company’s directors who are independent concerning such transactions.

General

This press release should not be construed as an offer to sell or a solicitation to purchase any of the securities mentioned herein within the United States. These securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws. Therefore, they cannot be offered or sold within the United States, or to or for the benefit of individuals in the United States or “U.S. Persons” (as defined in Regulation S under the U.S. Securities Act), unless registered under the U.S. Securities Act and relevant state securities laws, or if an exemption from such registration requirements applies.

About Innocan

Innocan operates as an innovator across the pharmaceutical and wellness industries. Within the pharmaceutical sector, Innocan has developed a CBD-loaded liposome drug delivery platform designed for precise dosing and the extended, controlled release of synthetic CBD, intended for non-opioid pain management. In the wellness sector, Innocan creates and distributes a diverse range of high-performance self-care and beauty products aimed at fostering a healthier lifestyle. Under this segment, Innocan conducts business through its 60% owned subsidiary, BI Sky Global Ltd., which specializes in advanced, targeted online sales.

The Company website is www.innocanpharma.com.

For further information, please contact:

For Innocan Pharma Corporation:
Iris Bincovich, CEO

+ 15162104025
+972-54-3012842
+442037699377 info@innocanpharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution regarding forward-looking information

Some details presented in this news release constitute forward-looking information as defined by relevant securities laws. Inherently, forward-looking information is susceptible to various risks and uncertainties, with some being outside Innocan’s direct control. The forward-looking statements in this news release are founded on specific key expectations and assumptions made by Innocan, including those pertaining to the Offering’s terms, timing, potential completion, and the intended use of its proceeds.

Forward-looking information is subject to diverse risks and uncertainties that could lead to actual outcomes and experiences differing significantly from the anticipated results or expectations stated in this news release. Principal risks and uncertainties encompass, but are not limited to: the Company’s capacity to meet the closing conditions of the Offering; the possibility that the Offering may not be finalized as per the stated terms and timeline, or at all; potential deviations in the Company’s use of the Offering’s proceeds from what was indicated; global and national economic, political, market, and business conditions; governmental and regulatory mandates and actions by authorities; and potential disruptions in relationships with suppliers, manufacturers, customers, business partners, and competitors. Furthermore, risks inherent in product distribution exist, such as import/export issues and the failure to secure necessary regulatory and other approvals (or to do so promptly). The projected market entry timeline might shift due to various factors, including the inability to obtain essential regulatory requirements or the need for more time to finalize and/or fulfill manufacturing and distribution agreements. Consequently, readers are advised against placing excessive reliance on the forward-looking information presented in this news release. A thorough examination of other risks affecting Innocan is available in Innocan’s public disclosures and filings, accessible under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned not to place undue reliance on forward-looking information, as actual results could differ substantially from what is projected. Innocan disclaims any obligation to update, correct, or revise any forward-looking information due to new information, future events, or other circumstances, unless mandated by applicable law.

Logo – http://rssdatabase.tickerwit.com/images/155/114155_2.jpg